

# International Nonproprietary Names for Pharmaceutical Substances (INN)

---

## RECOMMENDED International Nonproprietary Names (Rec. INN): List 39

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No 9, 1996*.

## Dénominations communes internationales des Substances pharmaceutiques (DCI)

---

### Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 39

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43 R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No 9, 1996*.

## Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

---

### Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 39

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

Discussions have recently taken place between the World Intellectual Property Organization and WHO's Division of Drug Management and Policies regarding the **protection of International Nonproprietary Names (INN)** against (mis)use as domain names on INTERNET. These discussions were initiated *inter alia* in view of INN having been registered as domain names on Internet, for purposes not necessarily related to the global identification of a specific pharmaceutical substance to protect the safety of patients. In this regard, there have been several reported cases where an INN-based domain name has been registered on the Internet and then sold to a company which had an interest in avoiding proprietary use of the INN in question.

In order to help ensure that INN are used exclusively for the identification of a specific pharmaceutical substance under one single, globally available name and that no party can claim any proprietary rights to INN, a paragraph relating to INN has been proposed for inclusion in the *Trademark Dispute Resolution, Draft Substantive Guidelines concerning Administrative Domain Name Challenge Panels*. Details are available on:

<http://www.gtld-mou.org/docs/tracps.htm> and  
<http://www.wipo.int/eng/internet/domains/index.htm>

After further consultation, it is suggested that the text of the proposed paragraph, as contained in clause 1 (b) of Annex B of the *Guidelines*, should read as follows<sup>a</sup>:

*"A name published by the World Health Organization (WHO) in the Cumulative List of International Nonproprietary Names for Pharmaceutical Substances (INN), and updated regularly in WHO Drug Information, pursuant to World Health Assembly (WHA) Resolution 3.11 and subsequent resolutions"*

It is hoped that the inclusion of this paragraph will allow interested parties to challenge the registration of a domain name "if identical or confusingly identical" to an INN, in particular if such a registration has been made in bad faith.

WHO would like to emphasize that its main concern is the safety of patients. In accordance with WHA resolution 3.11 on Non-proprietary Names for Drugs (adopted in May 1950 by the Third World Health Assembly), the Organization is responsible for selecting and promoting the protection of recommended International Nonproprietary Names as a means of identifying pharmaceutical substances under one single, globally available name, in which no party can claim any proprietary rights.

For any further information or comments, please contact the Secretariat of the INN Programme (Division of Drug Management and Policies, World Health Organization, 20 av. Appia, CH-1211 Geneva 27, Fax: +41 22 791 4730, e-mail: [koppkubels@who.ch](mailto:koppkubels@who.ch)).

<sup>a</sup> Based on the third revised draft of the *Guidelines* dated 16 January 1998.

Latin, English, French, Spanish.

Recommended INN


Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

**acidum iocanlidicum (<sup>123</sup>I)**iocanlidic acid (<sup>123</sup>I)15-(*p*-[<sup>123</sup>I]iodophenyl)pentadecanoic acidacide iocanlidique (<sup>123</sup>I)acide 15-(4-[<sup>123</sup>I]iodophényl)pentadécanoïqueácido iocanlidico (<sup>123</sup>I)ácido 15-(*p*-[<sup>123</sup>I]iodofenil)pentadecanoicoC<sub>21</sub>H<sub>33</sub><sup>123</sup>IO<sub>2</sub>**acrezastum**


acrezast

*N,N'*-(2-chloro-5-cyano-*m*-phenylene)bis(glycolamide)diacetate (ester)

acréozast

diacétate de 2,2'-[2-chloro-5-cyano-1,3-phénylènebis(imino)]bis(2-oxoéthyle)

acrezast

éster diacético de *N,N'*-(2-cloro-5-ciano-*m*-fenilén)bis(glicolamida)C<sub>15</sub>H<sub>14</sub>ClN<sub>3</sub>O<sub>6</sub>**argatrobanum**

argatroban



(2*R*,4*R*)-4-methyl-1-[(*S*)-*N*<sup>2</sup>-[[[(*RS*)-1,2,3,4-tetrahydro-3-methyl-8-quinolyl]-sulfonyl]arginyl]pipecolic acid

argatroban

acide (2*R*,4*R*)-4-méthyl-1-[(*S*)-*N*<sup>2</sup>-[[[(*RS*)-1,2,3,4-tetrahydro-3-méthyl-8-quinolyl]-sulfonyl]arginyl]pipecolique

argatroban

ácido (2*R*,4*R*)-4-metil-1-[(*S*)-*N*<sup>2</sup>-[[[(*RS*)-1,2,3,4-tetrahydro-3-metil-8-quinolil]-sulfonyl]arginil]pipecólico

**aseripidum**

aseripide



(2*R*,4*R*)-3-[*N*-[[3-[(*S*)-1-carboxyethyl]phenyl]carbonyl]glycyl]-  
2-(*o*-fluorophenyl)-4-thiazolidinecarboxylic acid, 4-*tert*-butylester

asérípide

acide (2*S*)-2-[3-[2-[2-(2*R*,4*R*)-4-[(1,1-diméthyléthoxy)carbonyl]-  
2-(2-fluorophényl)thiazolidin-3-yl]-2-oxoéthyl]uréido]phényl]propanoïque

aserípida

(2*R*,4*R*)-3-[*N*-[[3-[(*S*)-1-carboxietil]fenil]carbamoil]glicil]-  
2-(*o*-fluorofenil)-4-tiazolidinacarboxilato de *tert*-butilo

**avotermimum**

avotermín



transforming growth factor β3 (human), dimer

avotermine

facteur de croissance transformant β3 (humain)

avotermína

factor β3 de crecimiento transformador(humano), dímero



**cedelizumabum**

cedelizumab

immunoglobulin G 4 (human-mouse monoclonal OKTcd4a complementary determining region-grafted  $\gamma$ -chain anti-human CD 4 antigen), disulfide with human-mouse monoclonal OKTcd4a complementary determining region-grafted  $\kappa$ -chain, dimer

cédélizumab

immunoglobuline G 4 (chaîne  $\gamma$  de l'anticorps monoclonal de souris humanisé OKTcd4a dirigé contre l'antigène CD 4 humain), dimère du disulfure avec la chaîne  $\kappa$  de l'anticorps monoclonal de souris humanisé OKTcd4a

cedelizumab

inmunoglobulina G 4 (cadena  $\gamma$  del anticuerpo monoclonal humanizado de ratón OKTcd4a, dirigido contra el antígeno CD4 humano), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo monoclonal humanizado de ratón OKTcd4a

**ceftizoximum alapivoxilum**

ceftizoxime alapivoxil


(+)-(pivaloyloxy)methyl (6R,7R)-7-[2-[2-(L-alanyl amino)thiazol-4-yl]glyoxylamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 7<sup>2</sup>-(Z)-(O)-methyloxime)

ceftizoxime alapivoxil

(+)-(6R,7R)-7-[[2-[2-[(2S)-2-aminopropanoyl]amino]thiazol-4-yl]-2-[(Z)-méthoxyimino]acétyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ène-2-carboxylate de [(2,2-diméthylpropanoyl)oxy]méthyle

ceftizoxima alapivoxilo

(6R,7R)-7-[2-[2-(L-alanil amino)thiazolin-4-il]glioxilamido]-8-oxo-5-tia-1-azabicyclo[4.2.0]oct-2-en-2-carboxilato de (+)-pivaloxi)metil, 7<sup>2</sup>-(Z)-(O)-methioxime)

C<sub>22</sub>H<sub>26</sub>N<sub>6</sub>O<sub>8</sub>S<sub>2</sub>**celgosivirum**

celgosivir


(1S,6S,7S,8R,8aR)-octahydro-1,7,8-trihydroxy-6-indoliziny] butyrate

celgosivir

butanoate de (1S,6S,7S,8R,8aR)-1,7,8-trihydroxyoctahydroindolizin-6-yle

celgosivir

butrato de (1S,6S,7S,8R,8aR)-1,7,8-trihidroxi octahidro 6-indoliziniilo

C<sub>12</sub>H<sub>22</sub>NO<sub>5</sub>

**clenoliximabum**

clenoliximab

immunoglobulin G 4 (human-Macaca monoclonal CE9γ4PE γ4-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9γ4PE κ-chain, dimer

clenoliximab

immunoglobuline G 4 (chaîne γ4 de l'anticorps monoclonal chimérique homme-Macaque CE9γ4PE dirigé contre l'antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-Macaque CE9γ4PE

clenoliximab

inmunoglobulina G 4 (cadena γ4 del anticuerpo monoclonal quimérico hombre-Macaca CE9γ4PE dirigido contra el antígeno antigen CD 4 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal quimérico hombre-Macaca CE9γ4PE

**colesevelamum**

colesevelam

allylamine polymer with 1-chloro-2,3-epoxypropane, [6-(allylamino)hexyl]=trimethylammonium chloride and *N*-allyldecylamine

colésévélam

copolymère de prop-2-én-1-amine, de dodécan-1-amine et de *N,N,N*-triméthyl-6-(prop-2-énylamino)hexan-1-aminium réticulé à l'aide de 2-(chlorométhyl)oxirane (épichlorhydrine)

colesevelam

copolímero de prop-2-en-1-amino, de dodecan-1-amino y de *N,N,N*-trimetil-6-(prop-2-enilamino)hexan-1-aminio reticulado con 2-(clorometil)oxirano (epiclorhidrina)**deltibantum**

deltibant

D-arginyll-L-arginyll-L-prolyl-*trans*-4-hydroxy-L-prolylglycyl-L-phenylalanyl-L-cysteinyl-D-phenylalanyl-L-leucyl-L-arginine, 7,7'-bis(sulfide) with (2*R*,2'*S*)-*N,N'*-hexamethylenebis[2-mercaptosuccinimide]


deltibant

*S*<sup>7</sup>,*S*<sup>7'</sup>-[hexane-1,6-diylbis[(3*R*,3'*S*)-2,5-dioxopyrrolidin-1,3-diyl]]bis[D-arginyll-L-arginyll-L-prolyl-[(4*R*)-4-hydroxy-L-prolyl]-glycyl-L-phénylalanyl-L-cystéinyl-L-phénylalanyl-L-leucyl-L-arginine]

deltibant

D-arginil-L-arginil-L-proil-*trans*-4-hidroxi-L-proliiglicil-L-fenilalanil-L-cisteinil-D-fenilalanil-L-leucil-L-arginina, 7,7'-bis(sulfuro) con (2*R*,2'*S*)-*N,N'*-hexametilenbis[2-mercaptosuccinimida]C<sub>126</sub>H<sub>194</sub>N<sub>40</sub>O<sub>28</sub>S<sub>2</sub>

D-Arg—Arg—Pro—Hyp—Gly—Phe—Cys—D-Phe—Leu—Arg



D-Arg—Arg—Pro—Hyp—Gly—Phe—Cys—D-Phe—Leu—Arg

**eniluracilum**

eniluracil


5-ethynyluracil

eniluracil

5-éthynylpyrimidine-2,4(1*H*,3*H*)-dione

eniluracilo

5-etiniluracilo

 $C_8H_4N_2O_2$ **enlimomabum pegolum**

enlimomab pegol

immunoglobulin G 2a (mouse monoclonal BI-RR-1 anti-human antigen CD 54), disulfide with mouse monoclonal BI-RR-1 light chain, dimer, reaction product with  $\alpha$ -(2-carboxyethyl)- $\omega$ -methoxypoly(oxy-1,2-ethanediyl)

enlimomab pégol

*N*, *N'*, *N''*, *N'''*, *N''''*-pentakis[ $\alpha$ -méthylpoly(oxyéthylène)- $\omega$ -(oxypropanoyl)]immunoglobuline G2a (anticorps monoclonal de souris BI-RR-1 dirigé contre l'antigène CD 54 humain), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris BI-RR-1

enlimomab pegol

inmunoglobulina G 2a (anticuerpo monoclonal de ratón BI-RR-1 dirigido contra el antígeno CD 54 humano), dímero del disulfuro con la cadena ligera del anticuerpo de ratón BI-RR-1, producto de reacción con  $\alpha$ -(2-carboxietil)- $\omega$ -metoxipoli(oxi-1,2-etanodil)

**eplerenonum**

eplerenone


9,11 $\alpha$ -epoxy-17-hydroxy-3-oxo-17 $\alpha$ -pregn-4-ene-7 $\alpha$ ,21-dicarboxylic acid,  $\gamma$ -lactone, methyl ester

éplérénone

(2'*R*)-9,11 $\alpha$ -epoxy-3,5'-dioxo-4',5'-dihydrospiro[androst-4-ène-17, 2'(3*H*)-furane]-7 $\alpha$ -carboxylate de méthyle


eplerenona

éster metílico de la  $\gamma$ -lactona del ácido 9,11 $\alpha$ -epoxi-17-hidroxi-3-oxo-17 $\alpha$ -pregn-4-en-7 $\alpha$ ,21-dicarboxílico

 $C_{24}H_{30}O_8$ 

<b>felvizumabum</b>	
felvizumab	immunoglobulin G 1 (human-mouse monoclonal, $\gamma$ -chain anti-respiratory syncytial virus), disulfide with human-mouse monoclonal $\kappa$ -chain, dimer
felvizumab	immunoglobuline G 1 (chaîne $\gamma$ de l'anticorps monoclonal de souris humanisé dirigé contre le virus syncytial respiratoire), dimère du disulfure avec la chaîne $\kappa$ de l'anticorps monoclonal de souris humanisé
felvizumab	inmunoglobulina G 1 (cadena $\gamma$ del anticuerpo monoclonal humanizado de ratón, dirigido contra el virus sincitial respiratorio), dímero del disulfuro con la cadena $\kappa$ del anticuerpo humanizado de ratón
<b>follitropinum beta</b>	
follitropin beta	follicle-stimulating hormone, glycoform $\beta$ $\alpha$ -subunit: chorionic gonadotropin (human $\alpha$ -subunit protein moiety reduced) $\beta$ -subunit: follicle-stimulating hormone (human $\beta$ -subunit protein moiety reduced)
follitropine bêta	hormone folliculo-stimulante, forme glycosylée $\beta$ sous-unité $\alpha$ : gonadotropine chorionique (partie protéique réduite de la sous-unité $\alpha$ humaine) sous-unité $\beta$ : hormone folliculo-stimulante (partie protéique réduite de la sous-unité $\beta$ humaine)
folitropina beta	hormona estimulante del foliculo, glicoforma $\beta$ subunidad $\alpha$ : gonadotropina coriónica (fracción proteica reducida de la subunidad $\alpha$ humana) subunidad $\beta$ : hormona estimulante del foliculo (fracción proteica reducida de la subunidad $\beta$ )  $\alpha$ : C <sub>437</sub> H <sub>682</sub> N <sub>122</sub> O <sub>134</sub> S <sub>13</sub> $\beta$ : C <sub>538</sub> H <sub>633</sub> N <sub>145</sub> O <sub>171</sub> S <sub>13</sub>  APDVQDCPEC TLQENPFFSQ PGAPILQCMG CCFSRAYPT LRSKKTMLVQ KNVTSSTCC VAKSYNRVTV MGGFKVENH ACHCSTCYHH KS NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVY DPAKPQIKT CTFKELVYET VRVPGCAHHA DSLYTPVA QCHCGKCDSD STDCTVRGLG PSYCSFGEMK E
<b>fudosteinum</b>	
fudosteine	(-)-3-[(3-hydroxypropyl)thio]-L-alanine
fudostéine	(-)-acide (2R)-2-amino-3-[(3-hydroxypropyl)sulfanyl]propanoïque
fudosteína	(-)-3-[(3-hidroxiopropil)tio]-L-alanina



**gavestinelum**

gavestinel


4,6-dichloro-3-[(E)-2-(phenylcarbamoyl)vinyl]indole-2-carboxylic acid

gavestinel

acide 4,6-dichloro-3-[(E)-2-(phénylcarbamoyl)éthényl]-1H-indole-2-carboxylique

gavestinel

ácido 4,6-dicloro-3-[(E)-2-(fenilcarbamoyl)vinil]indol-2-carboxílico

**glufosfamidum**



glufosfamide

 $\beta$ -D-glucopyranose 1-[N,N'-bis(2-chloroethyl)phosphorodiamidate]

glufosfamide

N,N'-bis(2-chloroéthyl)phosphorodiamidate de  $\beta$ -D-glucopyranosyle

glufosfamida

1-[N,N'-bis(2-cloroetil)fosforodiamidato] de  $\beta$ -D-glucopiranosas**infiximabum**

infiximab

immunoglobulin G (human-mouse monoclonal cA2 heavy chain anti-human tumor necrosis factor), disulfide with human-mouse monoclonal cA2 light chain, dimer

infiximab

immunoglobuline G (chaîne lourde de l'anticorps monoclonal chimérique homme-souris cA2 dirigé contre le facteur de nécrose tumorale humaine), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme-souris cA2

infiximab

immunoglobulina G (cadena pesada del anticuerpo monoclonal quimérico hombre-ratón cA2 dirigido contra el factor de necrosis tumoral humano), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre-ratón cA2

**interferonum alfacon-1**

interferon alfacon-1

*N*-L-methionyl-22-L-arginine-76-L-alanine-78-L-aspartic acid-79-L-glutamic acid-86-L-tyrosine-90-L-tyrosine-156-L-threonine-157-L-asparagine-158-L-leucineinterferon  $\alpha$ 1 (human lymphoblast reduced)

interféron alfacon-1

*N*-L-méthionyl-[22-L-arginine-76-L-alanine-78-L-acide aspartique-79-L-acide glutamique-86-L-tyrosine-90-L-tyrosine-156-L-thréonine-157-L-asparagine-158-L-leucine]interféron  $\alpha$ 1 (lymphoblastique humain réduit)

interferón alfacón-1

*N*-L-metionil-22-L-arginina-76-L-alanina-78-ácido L-aspartico-79-ácido L-glutámico-86-L-tirosina-90-L-tirosina-156-L-treonina-157-L-asparagina-158-L-leucinainterferón  $\alpha$ 1 (linfoblástico humano reducido)

C<sub>670</sub>H<sub>1366</sub>N<sub>236</sub>O<sub>259</sub>S<sub>9</sub>

```

MCDLPQTHSLG  NRRALILLAQ  MRRISPFSCSL  KDRHDFGFPQ
EEFDGNQFQK   AQAISVLHEM  IQQTFNLFST   KDSSAAWDES
LLEKFYTELY    QQLNDLEACV  IQEVGVEETP   LMNVDSILAV
KKYFQRITLY    LTEKKYSPCA  WEVVRAEIMR   SFSLSSTNLQE
RLRRKE

```

**lanepitantum**

lanepitant

*N*-[(*R*)-2-indol-3-yl-1-[[*N*-(*o*-methoxybenzyl)acetamido] methyl]ethyl] [1,4'-bipipendine]-1'-acetamide


lanépitant

*N*-[(1*R*)-1-[[acétyl(2-méthoxybenzyl)amino]méthyl]-2-(1*H*-indol-3-yl)éthyl]-2-(1,4'-bipéridin-1'-yl)acétamide

lanepitant

*N*-[(*R*)-2-indol-3-il-1-[[*N*-(*o*-metoxibencil)acetamido]metil]etil] [1,4'-bipiperidina]-1'-acetamida

C<sub>33</sub>H<sub>45</sub>N<sub>5</sub>O<sub>3</sub>

**licostinelum**

licostinel



6,7-dichloro-1,4-dihydro-5-nitro-2,3-quinoxalinedione

licostinel

6,7-dichloro-5-nitro-1,4-dihydroquinoxaline-2,3-dione

licostinel

6,7-dicloro-1,4-dihidro-5-nitro-2,3-quinoxalinadiona

**lumefantrinum**



lumefantrine

(±)-2,7-dichloro-9-[(Z)-*p*-chlorobenzylidene]-α[(dibutylamino)methyl]fluorene-4-methanol

luméfantrine

(1*RS*)-2-(dibutylamino)-1-[(Z)-2,7-dichloro-9-(4-chlorobenzylidène)-9*H*-fluorén-4-yl]éthanol

lumefantrina

(±)-2,7-dichloro-9-[(Z)-*p*-chlorobenzylidene]-α[(dibutylamino)methyl]fluorene-4-methanoland enantiomer  
et énantiomère  
y enantiomero**milacainidum**



milacainide

(-)-(*R*)-2-amino-*N*-[3-(3-pyridyl)propyl]-2',6'-propionoxylidide

milacainide

(-)-(*R*)-2-amino-*N*-(2,6-diméthylphényl)-*N*-[3-(pyridin-3-yl)propyl]propanamide

milacainida

(-)-(*R*)-2-amino-*N*-[3-(3-piridil)propil]-2',6'-propionoxilidida


**mivobulinum**

mivobulin ethyl (S)-5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-*b*]pyrazine-7-carbamate

mivobuline [(2*S*)-5-amino-2-méthyl-3-phényl-1,2-dihydropyrido[3,4-*b*]pyrazin-7-yl]carbamate d'éthyle

mivobulina (S)-5-amino-1,2-dihidro-2-metil-3-fenilpirido [3,4-*b*]pirazina-7-carbamato de etilo

C<sub>17</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>


**nateglinidum**

nateglinide (-)-*N*-[(*trans*-4-isopropylcyclohexyl)carbonyl]-D-phenylalanine

natéglinide (-)-acide (2*R*)-2-[[[*trans*-4-(1-méthyléthyl)cyclohexyl]carbonyl]amino]-3-phénylpropanoïque

nateglinida (-)-*N*-[(*trans*-4-isopropilciclohexil)carbonil]-D-fenilalanina

C<sub>19</sub>H<sub>27</sub>NO<sub>3</sub>

**nonacogum alfa**

nonacog alfa blood-coagulation factor IX (human), glycoform  $\alpha$

nonacog alfa facteur IX de coagulation sanguine humaine, glycoforme  $\alpha$


nonacog alfa factor IX (humano) de la coagulación sanguínea, forma glucosilada  $\alpha$

**oberadilolum**

oberadilol ( $\pm$ )-4-chloro-2-[3-[[1,1-dimethyl-2-[*p*-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)anilino]ethyl]amino]-2-hydroxypropoxy]benzonitrile

obéradilol 4-chloro-2-[3-[[1,1-diméthyl-2-[[4-(4-méthyl-6-oxo-1,4,5,6-tétrahydropyridazin-3-yl)]phényl]amino]éthyl]amino]-2-hydroxypropoxy]benzonitrile

oberadilol ( $\pm$ )-4-cloro-2-[3-[[1,1-dimetil-2-[*p*-(1,4,5,6-tetrahidro-4-metil-6-oxo-3-piridazinil)anilino]etil]amino]-2-hidroxiopropoxi]benzonitrilo

$C_{25}H_{30}ClN_5O_3$ **opanixilum**


opanixil

4-amino-2-(4,4-dimethyl-2-oxo-1-imidazolidinyl)-N-ethyl-α,α,α-trifluoro-5-pyrimidinecarboxy-*m*-toluidide

opanixil

4-amino-2-(4,4-diméthyl-2-oxoimidazolidin-1-yl)-N-éthyl-N-[3-(trifluorométhyl)phényl]pyrimidin-5-carboxamide

opanixilo

4-amino-2-(4,4-dimetil-2-oxo-1-imidazolidinil)-N-etil-α,α,α-trifluoro-5-pirimidinacarboxi-*m*-toluidida $C_{19}H_{21}F_3N_6O_2$ **oraziponum**


orazipone

3-[*p*-(methylsulfonyl)benzylidene]-2,4-pentanedione

orazipone

3-[4-(méthylsulfonyl)benzylidène]pentane-2,4-dione

orazipona

3-[*p*-(metilsulfonyl)benzyliden]-2,4-pentanodiona $C_{13}H_{14}O_4S$ 

**pegmusirudinum**

pegmusirudin

L-valyl-L-valyl-L-tyrosyl-L-threonyl-L- $\alpha$ -aspartyl-L-cysteinyl-L-threonyl-L- $\alpha$ -glutamyl-L-serylglycyl-L-glutamyl-L-asparaginyll-leucyl-L-cysteinyl-L-leucyl-L-cysteinyl-L- $\alpha$ -glutamylglycyl-L-seryl-L-asparaginyll-valyl-L-cysteinylglycyl-L-glutamylglycyl-L-asparaginyll- $N^6$ -carboxyl-lysyl-L-cysteinyl-L-isoleucyl-L-leucylglycyl-L-seryl- $N^6$ -carboxyl-lysylglycyl-L- $\alpha$ -glutamyl-L-arginyl-L-asparaginyll-glutamyl-L-cysteinyl-L-valyl-L-threonylglycyl-L- $\alpha$ -glutamylglycyl-L-threonyl-L-prolyl-L-arginyl-L-prolyl-L-glutamyl-L-seryl-L-histidyl-L-asparaginyll- $\alpha$ -aspartylglycyl-L- $\alpha$ -aspartyl-L-phenylalanyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-isoleucyl-L-prolyl-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-tyrosyl-L-leucyl-L-glutamine cyclic (6  $\rightarrow$  14), (16  $\rightarrow$  28), (22  $\rightarrow$  39)-tris(disulfide), 27,33-diester with polyethylene glycol monoethyl ether


pegmusirudine

$N^6$  27,  $N^6$  33-bis[ $\alpha$ -méthylpoly(oxyéthylène)- $\omega$ -(oxycarbonyl)]-[33-L-lysine-36-L-arginine-47-L-arginine]- $O^{63}$ -désulfohirudine (*hirudo medicinalis*)

pegmusirudina

L-valil-L-valil-L-tirosil-L-treonil-L- $\alpha$ -aspartil-L-cisteinil-L-treonil-L- $\alpha$ -glutamil-L-serilglycil-L-glutamyl-L-asparaginyll-leucil-L-cisteinil-L-leucil-L-cisteinil-L- $\alpha$ -glutamylglycil-L-seril-L-asparaginyll-valil-L-cisteinilglycil-L-glutamylglycil-L-asparaginyll- $N^6$ -carboxi-L-ilisil-L-cisteinil-L-isoleucil-L-leucilglycil-L-seril- $N^6$ -carboxi-L-lisilglycil-L- $\alpha$ -glutamyl-L-arginil-L-asparaginyll-glutamyl-L-cisteinil-L-valil-L-treonilglycil-L- $\alpha$ -glutamylglycil-L-treonil-L-proil-L-arginil-L-proil-L-glutamyl-L-seril-L-histidil-L-asparaginyll- $\alpha$ -aspartilglycil-L- $\alpha$ -aspartil-L-fenilalanil-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-isoleucil-L-proil-L- $\alpha$ -glutamyl-L- $\alpha$ -glutamyl-L-tirosil-L-leucil-L-glutamine tris(disulfuro) ciclico (6  $\rightarrow$  14), (16  $\rightarrow$  28), (22  $\rightarrow$  39), 27,33-diester con polietilen glicol monoetil eter

$(C_2H_4O)_n (C_2H_4O)_n C_{302}H_{451}N_{85}O_{112}S_6$

**pifonakinum**

pifonakin

36-L-aspartic acid-141-L-serineinterleukin 1 $\alpha$  (human clone p10A)

pifonakine

[36-acide L-aspartique-141-L-sérine]interleukine 1 $\alpha$  (clone humain p10A)

pifonakina

36-L-ácido aspártico-141-L-serinainterleuquina 1 $\alpha$  (clon humano p10A)

SAPFSFLSNV KYNFMRIKY EFILNDALNQ SIIRADDQYL  
 TAAALHNLDE AVKFDMGAYK SSKDDAKITV ILRISKTLQY  
 VTAQDEDQPV LLKEMPEIPK TITGSETNLL FFWETHGTFK  
 YFTSVAHPNL FIATKQDYWV SLAGGPPSIT DFQILENQA

**pleconarilum**

pleconaril

3-[4-[3-(3-methyl-5-isoxazolyl)propoxy]-3,5-xylyl]-5-(trifluoromethyl)-  
 1,2,4-oxadiazole


pléconaril

3-[3,5-diméthyl-4-[3-(3-méthylisoxazol-5-yl)propoxy]phényl]-5-  
 (trifluorométhyl)-1,2,4-oxadiazole

pleconarilo

3-[4-[3-(3-metil-5-isoxazolil)propoxi]-3,5-xilil]-5-(trifluorometil)-1,2,4-oxadiazol

$C_{18}H_{18}F_3N_3O_3$

**pralmorelinum**

pralmorelin

D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-  
 L-lysineamide


pralmoreline

D-alanyl-[3-(naphthalén-2-yl)-D-alanyl]-L-alanyl-L-tryptophyl-D-phénylalanyl-  
 L-lysineamide

pralmorelina

D-alanil-3-(2-naftil)-D-alanil-L-alanil-L-triptofil-D-fenilalanil-L-lisnamida

$C_{45}H_{55}N_5O_6$



D-Ala-D-Ala-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>

**promazinum**

promazine


10-(3-dimethylaminopropyl)phenothiazine

promazine

(diméthylamino-3-propyl)-10-aza-1-phénothiazine

promazina

10-(3-dimetilaminopropil)fenotiazina

$C_{17}H_{20}N_2S$ **rituximabum**

rituximab

immunoglobulin G 1 (human-mouse monoclonal IDEC-C2B8  $\gamma$ 1-chain anti-human antigen CD 20), disulfide with human-mouse monoclonal IDEC-C2B8  $\kappa$ -chain, dimer

rituximab

immunoglobuline G1 (chaîne  $\gamma$ 1 de l'anticorps monoclonal chimérique homme-souris IDEC-C2B8 dirigé contre l'antigène CD20 humain), dimère du disulfure avec la chaîne  $\kappa$  de l'anticorps monoclonal chimérique homme-souris IDEC-C2B8

rituximab

inmunoglobulina G 1 (cadena  $\gamma$ 1 del anticuerpo monoclonal quimérico hombre-ratón IDEC-C2B8 dirigido contra el antígeno CD 20 humano), dímero del disulfuro con la cadena  $\kappa$  del anticuerpo monoclonal quimérico hombre-ratón IDEC-C2B8

**rivastigminum**

rivastigmine


(-)-*m*-[1-(dimethylamino)ethyl]phenyl ethylmethylcarbamate

rivastigmine

(-)-éthylméthylcarbamate de 3-[(1*S*)-1-(diméthylamino)éthyl]phényle

rivastigmina

etilmetilcarbamato de (-)-*m*-[1-(dimetilamino)etil]fenilo

 $C_{14}H_{22}N_2O_2$ **roflumilastum**

roflumilast

3-(cyclopropylmethoxy)-*N*-(3,5-dichloro-4-pyridyl)-4-(difluoromethoxy)=benzamide


roflumilast


3-(cyclopropylméthoxy)-*N*-(3,5-dichloropyridin-4-yl)-4-(difluorométhoxy)=benzamide

roflumilast

3-(ciclopropilmetoxi)-*N*-(3,5-dicloro-4-piridil)-4-(difluorometoxi)benzamida





$C_{20}H_{28}N_4O_6$ **tazomelinum**

tazomeline


tazoméline

tazomelina

3-[4-(hexylthio)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridine

3-[4-(hexylsulfanyl)-1,2 5-thiadiazol-3-yl]-1-méthyl-1,2,5,6-tétrahydropyridine


3-[4-(hexiltio)-1,2,5-tiadiazol-3-il]-1,2,5,6-tetrahydro-1-metilpiridina

 $C_{14}H_{23}N_3S_2$ **terestigminum**

terestigmine

térestigmine

terestigmina

(4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahydro-2,4a,9-trimethyl-1,2-oxazino[6,5-*b*]indol-6-yl heptylcarbamateheptylcarbamate de (4a*S*,9a*S*)-2,4a,9-triméthyl-2,3,4,4a,9,9a-hexahydro-1,2-oxazino[6,5-*b*]indol-6-yleheptilcarbamato de (4a*S*,9a*S*)-2,3,4,4a,9,9a-hexahidro-2,4a,9-trimetil-1,2-oxazino[6,5-*b*]indol-6-ilo $C_{21}H_{33}N_3O_3$ 



**urokinasum alfa**

urokinase alfa

urokinase (enzyme-activating) (human clone pA3/pD2/pF1 high-molecular-weight isoenzyme protein moiety)

urokinase alfa

activateur du plasminogène (partie protéique de l'isoenzyme de masse moléculaire élevée fournie par le clone humain pA3/pD2/pF1)

urokinasa alfa

urokinasa, activador del plasminógeno (fracción proteica de la isoenzima de masa molecular elevada producida por el clon humano pA3/pD2/pF1)

**vatanidipinum**


vatanidipine

(±)-*p*-[4-(diphenylmethyl)-1-piperazinyl]phenethyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate

vatanidipine

(4*RS*)-2,6-diméthyl-4-(3-nitrophényl)-1,4-dihydropyridine-3,5-dicarboxylate de 2-[4-[4-(diphénylméthyl)pipérazin-1-yl]phényl]éthyle et de méthyle

vatanidipino

1,4-dihidro-2,6-dimetil-4-(*m*-nitrofenil)-3,5-piridinadicarboxilato de (±)-*p*-[4-(difenílmétil)-1-piperazinil]fenetilo y metilo  
C<sub>41</sub>H<sub>42</sub>N<sub>4</sub>O<sub>6</sub>and enantiomer  
et l'énantiomère  
y enantiómero**xylazinum**


xylazine

5,6-dihydro-2-(2,6-xylidino)-4*H*-1,3-thiazine

xylazine

2-(2,6-xylidino)-5,6-dihydro-4*H*-1,3-thiazine

xylazina

2-(2,6-xilidino)-5,6-dihidro-4*H*-1,3-tiazinaC<sub>12</sub>H<sub>16</sub>N<sub>2</sub>S

---

## AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES

### Recommended International Nonproprietary Names (Rec. INN): List 31 (WHO Drug Information, Vol. 5, No. 3, 1991)

p. 4     **dalteparinum natricum**  
dalteparin sodium

*replace the definition by the following.*

Sodium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 2-O-sulfo- $\alpha$ -L-idopyranosuronic acid structure at the non-reducing end and a 6-O-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain, the mass-average molecular mass ranges between 5600 and 6400 with a characteristic value of about 6000; the degree of sulfatation is 2.0 to 2.5 per disaccharidic unit

p. 10    **parnaparinum natricum**  
parnaparin sodium

*replace the definition by the following.*

Sodium salt of a low molecular mass heparin that is obtained by radical-catalyzed depolymerization, with hydrogen peroxide and with a cupric salt, of heparin from bovine or pork intestinal mucosa; the majority of the components have a 2-O-sulfo- $\alpha$ -L-idopyranosuronic acid structure at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine structure at the reducing end of their chain; the mass-average molecular mass ranges between 4000 and 6000 with a characteristic value of about 5000, the degree of sulfatation is 2.0 to 2.6 per disaccharidic unit

p. 11    **reviparinum natricum**  
reviparin sodium

*replace the definition by the following*

Sodium salt of a low molecular mass heparin that is obtained by nitrous acid depolymerization of heparin from porcine intestinal mucosa, the majority of the components have a 2-O-sulfo- $\alpha$ -L-idopyranosuronic acid structure at the non-reducing end and a 6-O-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain; the mass-average molecular mass ranges between 3150 and 5150, with a characteristic value of about 4150; the degree of sulfatation is about 2.1 per disaccharidic unit.

- p 16 **enoxaparinum natricum**  
enoxaparin sodium

*replace the definition by the following:*

Sodium salt of a low molecular mass heparin that is obtained by alkaline depolymerization of the benzyl ester derivative of heparin from porcine intestinal mucosa, the majority of the components have a 2-O-sulfo-4-desoxy-4- $\alpha$ -L-threo-hex-4-enopyranosuronic acid structure at the non-reducing end of their chain, the mass-average molecular mass ranges between 3500 and 5500 with a characteristic value of about 4500, the degree of sulfatation is about 2 per disaccharidic unit.

**Recommended International Nonproprietary Names (Rec. INN): List 32**  
(WHO Drug Information, Vol. 6, No. 3, 1992)

- p 10 **tinzaparinum natricum**  
tinzaparin sodium

*replace the definition by the following:*

Sodium salt of a low molecular mass heparin that is obtained by controlled enzymatic depolymerization of heparin from porcine intestinal mucosa using heparinase from *Flavobacterium heparinum*, the majority of the components have a 2-O-sulfo-4-desoxy-4- $\alpha$ -L-threo-hex-4-enopyranosuronic acid structure at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine structure at the reducing end of their chain; the mass-average molecular mass ranges between 5500 and 7500 with a characteristic value of about 6500; the degree of sulfatation is 1.8 to 2.5 per disaccharidic unit

**Recommended International Nonproprietary Names (Rec. INN): List 35**

**Dénominations communes internationales recommandées (DCI Rec.): Liste 35**

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 35**

(WHO Drug Information, Vol. 9, No. 3, 1995)

- p. 14 **itamelinum**  
itameline

*replace the chemical name by the following:*

(E)-p-chlorophenyl 3-formyl-5,6-dihydro-1(2H)-pyridinecarboxylate, O-methyloxime

itamelina

*sustituyase el nombre químico por lo siguiente:*

3-formil-5,6-dihidro-1(2H)-piridinacarboxilato de (E)- p-clorofenilo, O-metiloxima

- p 11 **eptacogum alfa (activatum)**  
eptacog alfa (activated)  
eptacog alfa (activé)  
eptacog alfa (activado)

*replace the molecular formula by the following:*

*remplacer la formule brute par.*

*sustituyase la fórmula empírica por.*

**C<sub>1982</sub>H<sub>3054</sub>N<sub>560</sub>O<sub>618</sub>S<sub>28</sub>**

**Recommended International Nonproprietary Names (Rec. INN): List 36****Dénominations communes internationales recommandées (DCI Rec.): Liste 36****Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 36***(WHO Drug Information, Vol. 10, No. 3, 1996)***p. 148 igovomabum**

igovomab

*replace the description by the following:*immunoglobulin G 1 (mouse monoclonal OC125 F(ab')<sub>2</sub> F(ab')<sub>2</sub> fragment anti-human ovarian cancer antigen CA 125), disulfide with mouse monoclonal OC125 F(ab')<sub>2</sub> light chain

igovomab

*remplacer la description par la suivante:*fragment F(ab')<sub>2</sub> de l'anticorps monoclonal OC 125 F(ab')<sub>2</sub> dirigé contre l'antigène CA 125 associé à certaines tumeurs ovariennes

igovomab

*sustituyase la descripción por la siguiente:*fragmento F(ab')<sub>2</sub> del anticuerpo monoclonal OC 125 F(ab')<sub>2</sub> anti-antígeno CA 125 asociado a ciertos tumores ováricos**p. 160 thymalfasinum**


thymalfasin

*replace the molecular formula by the following:*

thymalfasine

*remplacer la formule brute par la suivante:*

timalfasina

*sustituyase la fórmula empírica por:***p. 154 palonosetronum**

palonosetron

*replace the chemical name and the molecular formula by the following.*

(3aS)-2,3,3a,4,5,6-hexahydro-2-[(3S)-3-quinuclidinyl]-1H-benz[de]isoquinolin-1-one

palonosétron


*remplacer le nom chimique et la formule brute par :*

(3aS)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolein-1-one

palonosetrón

*sustituyanse el nombre químico y la fórmula empírica por*

(3aS)-2,3,3a,4,5,6-tetrahydro-2-[(3S)-3-quinuclidinil]-1H-benz[de]isoquinolin-1-ona



**Dénominations communes internationales recommandées (DCI Rec.): Liste 31**  
*(Informations pharmaceutiques OMS, Vol. 5, No. 3, 1991)*

p. 5 **dalteparinum natricum**  
 daltéparine sodique

*remplacer la description par*

Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc, la majorité des composants de la daltéparine sodique possèdent une structure acide 2-O-sulfo- $\alpha$ -L-idopyranosurionique à l'extrémité non réductrice de leur chaîne et une structure 6-O-sulfo-2,5-anhydro-D-mannitol à l'extrémité réductrice de leur chaîne, la masse moléculaire relative moyenne est de 5600 à 6400, avec une valeur caractéristique de 6000 environ; le degré de sulfatation est de 2.0 à 2.5 par unité disaccharidique.

p. 10 **parnaparinum natricum**  
 parnaparine sodique

*remplacer la description par*

Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, à catalyse radicalaire, au moyen de peroxyde d'hydrogène et d'un sel de cuivre, d'héparine de muqueuse intestinale de boeuf ou de porc, la majorité des composants de la parnaparine sodique possèdent une structure acide 2-O-sulfo- $\alpha$ -L-idopyranosurionique à l'extrémité non réductrice de leur chaîne et une structure 2N,6-N,6-O-disulfo-D-glucosamine à l'extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 4000 à 6000, avec une valeur caractéristique de 5000 environ, le degré de sulfatation est de 2.0 à 2.6 par unité disaccharidique.

p. 17 **enoxaparinum natricum**  
 énoxaparine sodique

*remplacer la description par*

Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation alcaline de l'ester benzyle d'héparine de muqueuse intestinale de porc; la majorité des composants de l'énoxaparine sodique possèdent une structure acide 2-O-sulfo-4-désoxy-4- $\alpha$ -L-thréo-hex-4-énopyranosurionique à l'extrémité non réductrice de leur chaîne, la masse moléculaire relative moyenne est de 3500 à 5500, avec une valeur caractéristique de 4500 environ; le degré de sulfatation est de 2 par unité disaccharidique.

p. 12 **reviparinum natricum**  
 réviparine sodique

*remplacer la description suivante*

Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymérisation, au moyen d'acide nitreux, d'héparine de muqueuse intestinale de porc; la majorité des composants de la réviparine sodique possèdent une structure acide 2-O-sulfo- $\alpha$ -L-idopyranosurionique à l'extrémité non réductrice de leur chaîne et une structure 6-O-sulfo-2,5-anhydro-D-mannitol à l'extrémité réductrice de leur chaîne, la masse moléculaire relative moyenne est de 3150 à 5150, avec une valeur caractéristique de 4150 environ, le degré de sulfatation est 2.1 environ par unité disaccharidique.



**Dénominations communes internationales recommandées (DCI Rec.): Liste 32***(Informations pharmaceutiques OMS, Vol. 6, No. 3, 1992)***p. 10 tinzaparinum natricum**

tinzaparine sodique

*remplacer la description par:*

Sel sodique d'une héparine de basse masse moléculaire obtenue par dépolymerisation enzymatique contrôlée, au moyen de l'héparinase de *Flavobacterium heparinum*, d'héparine de muqueuse intestinale de porc; la majorité des composants de la tinzaparine sodique possèdent une structure acide 2-O-sulfo-4-désoxy-4- $\alpha$ -L-thréo-hex-4-énopyranosurionique à l'extrémité non réductrice de leur chaîne et une structure 6-N, 6-O-disulfo-D-glucosamine à l'extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est de 5500 à 7500, avec une valeur caractéristique de 6500 environ; le degré de sulfatation est de 1.8 à 2.5 par unité disaccharidique

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 31***(Información Farmacéutica, OMS, Vol. 5, No. 3, 1991)***p. 4 dalteparinum natricum**

dalteparina sódica

*sustituyase la descripción por la siguiente:*

Sal sódica de una heparina de baja masa molecular obtenida por despolimerización con ácido nítrico de la heparina de la mucosa intestinal de cerdo, la mayoría de los componentes tienen una estructura de ácido 2-O-sulfo- $\alpha$ -L-idopiranosurónico en el extremo no reductor y una estructura de 6-O-sulfo-2,5-anhidro-D-mannitol en el extremo reductor de la cadena, la masa molecular relativa media es de 5600 a 6400, con un valor característico de 6000 aproximadamente; el grado de sulfatación es de 2.0 a 2.5 por unidad de disacárido.

**p. 10 parnaparinum natricum**

parnaparina sódica

*sustituyase la descripción por la siguiente:*

Sal sódica de una heparina de baja masa molecular obtenida por despolimerización con peróxido de hidrógeno y un sal de cobre de la heparina de la mucosa intestinal de buey o de cerdo, la mayoría de los componentes tienen una estructura de ácido 2-O-sulfo- $\alpha$ -L-idopiranosurónico en el extremo no reductor y una estructura de 6-O-6-N-disulfo-D-glucosamina en el extremo reductor de la cadena, la masa molecular relativa media es de 4000 a 6000, con un valor característico de 5000 aproximadamente; el grado de sulfatación es de 2.0 a 2.6 por unidad de disacárido.

- p. 16 **enoxaparinum natricum**  
enoxaparina sódica

*sustituyase la descripción por la siguiente*

Sal sódica de una heparina de baja masa molecular obtenida por despolimerización alcalina del éster bencílico de la heparina de la mucosa intestinal de cerdo, la mayoría de los componentes tienen una estructura de ácido 2-O-sulfo-4-desoxi-4- $\alpha$ -L-*treo*-hex-4-enopiranosurónico en el extremo no reductor en el extremo reductor de la cadena; la masa molecular relativa media es de 3500 a 5500, con un valor característico de 4500 aproximadamente, el grado de sulfatación es de 2 por unidad de disacárido.

- p. 11 **reviparinum natricum**  
reviparina sódica

*sustituyase la descripción por la siguiente*

Sal sódica de una heparina de baja masa molecular obtenida por despolimerización con ácido nítrico de la heparina de la mucosa intestinal del cerdo; la mayoría de los compuestos tienen una estructura de ácido 2-O-sulfo- $\alpha$ -L-idopiranosurónico en el extremo no reductor y una estructura de 6-O-sulfo-2,5-anhidro-D-manitol en el extremo reductor de la cadena, la masa molecular relativa media está entre 3150 y 5150, un valor característico de 4150 aproximadamente, el grado de sulfatación es de 2.1 por unidad de disacárido.

**Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 32**  
(*Información Farmacéutica, OMS, Vol. 6, No. 3, 1992*)

- p. 9 **tinzaparinum natricum**  
tinzaparina sódica

*sustituyase la descripción por la siguiente*

Sal sódica de una heparina de baja masa molecular obtenida por despolimerización enzimática controlada con heparinasa de *Flavobacterium heparinum* de la heparina de la mucosa intestinal de cerdo; la mayoría de los componentes tienen una estructura de ácido 2-O-sulfo-4-desoxi-4- $\alpha$ -L-*treo*-hex-4-enopiranosurónico en el extremo no reductor y una estructura de 6-O-6-N-disulfo-D-glucosamina en el extremo reductor de la cadena, la masa molecular relativa media es de 5500 a 7500, con un valor característico de 6500 aproximadamente; el grado de sulfatación es de 1.8 a 2.5 por unidad de disacárido.

**Proposed International Nonproprietary Names (Rec. INN): List 35**

**Dénominations communes internationales proposées (DCI Rec.): Liste 35**

**Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Lista 35**

(*WHO Drug Information, Vol. 9, No. 3, 1995*)

- p. 25 **teverelixum**  
teverelix

*replace the chemical name by the following:*

*N*-acetyl-3-(2-naphthyl)-D-alanyl-p-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-*N*<sup>6</sup>-carbamoyl-D-lysyl-L-leucyl-*N*<sup>6</sup>-isopropyl-L-lysyl-L-prolyl-D-alaninamide

tévérélix	<i>remplacer le nom chimique par</i> [N-acétyl-3-(naphtalén-2-yl)-D-alanyl]-(4-chloro-D-phénylalanil)-[3-(pyridin-3-yl)-D-alanyl]-L-séryl-L-tyrosyl-[N <sup>6</sup> -(carbamoyl)-D-lysyl]-L-leucyl-[N <sup>6</sup> -(1-méthyléthyl)-L-lysyl]-L-prolyl-D-alaninamide
teverelix	<i>sustituyase el nombre químico por</i> [N-acetil-3-(naftalen-2-il)-D-alanil]-(4-cloro-D-fenilalanil)-[3-(piridin-3-il)-D-alanil]-L-seril-L-tirosil-[N <sup>6</sup> -(carbamoil)-D-lisil]-L-leucil-[N <sup>6</sup> -(1-metiletil)-L-lisil]-L-prolil-D-alaninamida

**Proposed International Nonproprietary Names (Rec. INN): List 38****Dénominations communes internationales proposées (DCI Rec.): Liste 38****Denominaciones Comunes Internacionales Propuestas (DCI Rec.): Liste 38***(WHO Drug Information, Vol. 11, No. 3, 1997)*

p 162	<b>bimoclomolum</b>	
	bimoclomol	<i>replace the chemical name by the following</i> (±)-N-(2-hydroxy-3-piperidinopropoxy)nicotinimidoyl chloride
p 175	<b>opratonii iodidum</b>	
	opratonium iodide	<i>replace the chemical name by the following:</i> trimethyl[3-(10-undecenamido)propyl]ammonium iodide
	ioduro de opratonio	<i>sustituyase el nombre químico por lo siguiente:</i> ioduro de trimetil[3-(10-undecenamido)propil]amonio
p 178	<b>tasonerminum</b>	
	tasonermin	<i>replace the graphic formula by the following.</i>
	tasonermine	<i>remplacer la formule développée par la suivante:</i>
	tasonermina	<i>sustituyase la fórmula desarrollada por la siguiente.</i>

```

VRSSRTPSD  KPVAHVVANP  QABGQLQWLN  RRANALLANG
VELRDNQLVV  PSEGLYLIYS  QVLFGQGSCP  STHVLLTHTI
SRIAVSYQTK  VNLLSAIKSP  CQRETPEGAE  AKPWYEPiYL
GGVFQLEKGD  RLSAEINRPD  YLDFAESGQV  YFGIIAL

```

**Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales**

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* ont été publiés avec la liste 77 des DCI proposées et seront, à nouveau, publiés avec la prochaine liste.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.